Mark Harvey
Corporate Officer/Principal bij The University of Queensland
Profiel
Mark Harvey is an Adjunct Associate Professor at The University of Queensland.
He previously worked as an Independent Non-Executive Director at Nuwellis, Inc. in 2012, as well as a Director at Pathway Therapeutics, Inc. and Pathway Therapeutics Ltd.
He was also a Director at Osprey Medical, Inc. from 2007 to 2011.
Additionally, he served as the Managing Director at Symbiosis Group Ltd.
and was a Partner at CM Capital Investments Pty Ltd.
from 2010 to 2012.
He was also an Investment Committee Member at ANU Connect Ventures Pty Ltd.
Dr. Harvey received his undergraduate, MBA, and doctorate degrees from The University of Queensland.
Actieve functies van Mark Harvey
Bedrijven | Functie | Begin |
---|---|---|
The University of Queensland | Corporate Officer/Principal | - |
Eerdere bekende functies van Mark Harvey
Bedrijven | Functie | Einde |
---|---|---|
CM Capital Investments Pty Ltd.
CM Capital Investments Pty Ltd. Investment ManagersFinance CM Capital Investments Pty Ltd is a venture capital firm, a subsidiary of Talu Ventures Pty Ltd founded in 1998 by Michael Begun and Carmel J. Hillyard, The firm is headquartered in Brisbane. | Director of Investments | 20-11-2012 |
NUWELLIS, INC. | Director/Board Member | 12-11-2012 |
OSPY MEDI CDI | Director/Board Member | - |
Symbiosis Group Ltd.
Symbiosis Group Ltd. Investment ManagersFinance Symbiosis Group Ltd. (Symbiosis) is a venture capital subsidiary of UniQuest Pty Ltd. founded in 2004.The firm headquartered in Queensland, Australia. | Private Equity Investor | 01-04-2006 |
Pathway Therapeutics, Inc.
Pathway Therapeutics, Inc. BiotechnologyHealth Technology Pathway Therapeutics, Inc. operates as a clinical stage, privately held, pharmaceutical company developing differentiated and best in class isoform specific PI3-kinase (PI3K) inhibitors for oncology, inflammatory and respiratory diseases. Its lead product include PWT33597, demonstrates excellent in vitro selectivity for its targets, with negligible activity against other protein kinases and other pharmacologically relevant targets at biologically active concentrations. The firm’s other product include PWT143, which has shown outstanding efficacy in in vivo models and has an excellent DMPK and safety profile suitable for advancement in multiple indications. The company was founded in 2010 by William A. Denny and Peter Robin Shepherd and is headquartered in San Francisco, CA. | Director/Board Member | - |
Opleiding van Mark Harvey
The University of Queensland | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
NUWELLIS, INC. | Health Technology |
Bedrijven in privébezit | 6 |
---|---|
Pathway Therapeutics, Inc.
Pathway Therapeutics, Inc. BiotechnologyHealth Technology Pathway Therapeutics, Inc. operates as a clinical stage, privately held, pharmaceutical company developing differentiated and best in class isoform specific PI3-kinase (PI3K) inhibitors for oncology, inflammatory and respiratory diseases. Its lead product include PWT33597, demonstrates excellent in vitro selectivity for its targets, with negligible activity against other protein kinases and other pharmacologically relevant targets at biologically active concentrations. The firm’s other product include PWT143, which has shown outstanding efficacy in in vivo models and has an excellent DMPK and safety profile suitable for advancement in multiple indications. The company was founded in 2010 by William A. Denny and Peter Robin Shepherd and is headquartered in San Francisco, CA. | Health Technology |
CM Capital Investments Pty Ltd.
CM Capital Investments Pty Ltd. Investment ManagersFinance CM Capital Investments Pty Ltd is a venture capital firm, a subsidiary of Talu Ventures Pty Ltd founded in 1998 by Michael Begun and Carmel J. Hillyard, The firm is headquartered in Brisbane. | Finance |
Pathway Therapeutics Ltd.
Pathway Therapeutics Ltd. Pharmaceuticals: OtherHealth Technology Pathway Therapeutics Ltd. developed drugs for the treatment of cancer. The company was founded in 2007 and was headquartered in Auckland, New Zealand. | Health Technology |
Osprey Medical, Inc.
Osprey Medical, Inc. Medical SpecialtiesHealth Technology Osprey Medical, Inc. engages in the development to prevent harmful effect of x-ray dye used during angiographic imaging procedures. Its product includes Dyevert system, which is designed to reduce the amount of dye contrast injected into the patients during standard cardiovascular procedures. The company was founded by Frank Solomon, David Kaye, and James Edward Shapland on August 31, 2005 and is headquartered in Minnetonka, MN. | Health Technology |
ANU Connect Ventures Pty Ltd.
ANU Connect Ventures Pty Ltd. Investment ManagersFinance ANU Connect Ventures Pty Ltd (ANU Connect Ventures) is a venture capital subsidiary of Australian National University founded in 2005. The firm is headquartered in Canberra, Australia. | Finance |
Symbiosis Group Ltd.
Symbiosis Group Ltd. Investment ManagersFinance Symbiosis Group Ltd. (Symbiosis) is a venture capital subsidiary of UniQuest Pty Ltd. founded in 2004.The firm headquartered in Queensland, Australia. | Finance |